Navigation Links
Biodel Inc. Announces Appointment of Alan Krasner, M.D. as Chief Medical Officer
Date:5/20/2008

DANBURY, Conn., May 20 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq: BIOD) today announced that Alan Krasner, M.D. has been appointed as the Company's Chief Medical Officer, effective May 27, 2008.

"The addition of Dr. Krasner to our team provides Biodel with strong internal clinical and regulatory leadership and we expect him to play an important role in the clinical development of our product candidates," said Dr. Solomon Steiner, Chief Executive Officer and Chairman of Biodel. "Dr. Krasner's depth of knowledge in endocrinology and insulin, coupled with his experience developing late stage drug candidates will be valuable in advancing our suite of VIAject(TM) products to market."

Dr. Andreas Pfuetzner, Biodel's current Chief Medical Officer will remain on Biodel's management team as the Company's Chief Medical Officer in Europe and as a member of the Company's Scientific Advisory Board.

"I look forward to working closely with my esteemed colleague to advance VIAject(TM) through the NDA phase of development," said Professor Dr. Andreas Pfuetzner.

Dr. Krasner joins the Company from Pfizer Global Research and Development where he was Director of the Department of Clinical Research Metabolic Diseases and responsible for the design, execution, clinical analysis, and reporting of multiple, global clinical trials supporting registration of late stage drug candidates. Dr. Krasner currently serves as a consulting physician at the Joslin Diabetes and Endocrinology Center of the Lawrence and Memorial Hospital in New London, Connecticut. Dr. Krasner holds a B.S. from the Medical Education Honors Program at Northwestern University and a M.D. from Northwestern University Medical School. He completed his residency at Johns Hopkins Hospital in internal medicine and subsequently received a fellowship from Johns Hopkins Hospital in endocrinology and metabolism.

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for endocrine disorders, such as diabetes and osteoporosis. Biodel's product candidates are developed by using VIAdel(TM) technology, which reformulates existing FDA-approved peptide drugs. The Company's lead product candidate, VIAject(TM), is an ultra rapid-acting injectable meal-time insulin in development for use by patients with Type 1 or Type 2 diabetes. VIAject(TM) is currently being tested in two pivotal Phase III clinical trials. Biodel's pipeline also includes VIAtab(TM), a sublingual tablet formulation of insulin in the Phase I stage of clinical testing, and two pre-clinical osteoporosis product candidates. For further information regarding Biodel, please visit the Company's website at http://www.biodel.com.

BIOD-G


'/>"/>
SOURCE Biodel Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Ralf Rosskamp, M.D. Joins Biodels Scientific Advisory Board
2. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
3. Biodel to Amend June 30, 2007 10-Q to Correct Non-Cash Share-Based Compensation Expense
4. Biodel Inc. to Present at BIO InvestorForum 2007 Conference on October 11, 2007
5. Biodel Inc. to Present at Natixis Bleichroeder Hidden Gems Conference on October 8, 2007
6. Brian J.G. Pereira, M.D. Joins Biodels Board of Directors
7. Biodel to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on December 11, 2007
8. Biodel Inc. Announces Pricing of Public Offering
9. Biodel Inc. to Announce First Quarter Fiscal Year 2008 Financial Results on February 14, 2008
10. Biodel Inc. Reports First Quarter Fiscal Year 2008 Financial Results
11. Biodel Inc. to Present at the BioCentury Future Leaders Conference on March 27th, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... MA (PRWEB) , ... June 23, 2016 , ... ... Peel Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute ... platform of microbial tests introduced last year,” stated Bob Salter, Vice President of ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , a ... $1 million in debt financing from Silicon Valley Bank ... automation and to advance its drug development efforts, as ... facility. "SVB has been an incredible strategic ... services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published ... how a patient who developed lymphedema after being treated for breast cancer benefitted from ... the paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
(Date:3/29/2016)... , March 29, 2016 ... "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to ... ink used in a variety of writing instruments, ensuring ... of originally created collectibles from athletes on LegacyXChange will ... analysis of the DNA. Bill Bollander ...
Breaking Biology News(10 mins):